GrayBella Capital

GrayBella Capital is a private, pan-European venture capital firm focused on growth-stage companies in HealthTech and DeepTech. In healthcare, it targets businesses in diagnostics, healthcare IT, patient monitoring, medical devices, biomarker discovery, and platform technologies that support life sciences and drug development. The firm appears to invest primarily from Series A through Series C and maintains operations in London and Boston, with additional presence in parts of Europe. Publicly visible portfolio examples include CN Bio, BC Platforms, Sensius, and atai-related investments. GrayBella Capital is an investor rather than a therapeutic drug developer, so it does not have an internal clinical pipeline in the conventional biotech sense.